Exclusive articles:
BBLG Announces Split as Pursuit of Breakthrough Treatment Continues
By Brad Sorensen, CFA
NASDAQ:BBLG
READ THE FULL BBLG RESEARCH REPORT
There are approximately 350,000 spinal fusion surgeries done in the US every year with varying degrees...
EPIX: Initial Data from Combination Trial of Masofaniten and Enzalutamide Expected in 2024…
By David Bautz, PhD
NASDAQ:EPIX
READ THE FULL EPIX RESEARCH REPORT
Business Update
Update on Masofaniten Clinical Programs
ESSA Pharma Inc. (NASDAQ:EPIX) is developing masofaniten (EPI-7386), its next-generation antigen...
BIOR: Capitalizing on Progress: BT-600 to Start
By John Vandermosten, CFA
NASDAQ:BIOR
READ THE FULL BIOR RESEARCH REPORT
Update on Programs and Capital Structure
Following the report of third quarter financial and operational results, Biora...
BCTX: Down in San Antone
By John Vandermosten, CFA
NASDAQ:BCTX
San Antonio Breast Cancer Symposium Poster Presentations
BriaCell Therapeutics Corp. (NASDAQ:BCTX) presented three posters at the 2023 San Antonio Breast Cancer Symposium...
ACHV: Not So Fast…
By John Vandermosten, CFA
NASDAQ:ACHV
READ THE FULL ACHV RESEARCH REPORT
Update to the Timeline
On December 11th, 2023, Achieve Life Sciences, Inc. (NASDAQ:ACHV) filed Form 8-K updating...
